Page 61

APA (American Psychiatric Association). 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA.

Atkinson WL, Hadler SC, Redd SB, Orenstein WA. 1992. Measles surveillance— United States, 1991. Mor Mortal Wkly Rep CDC Surveill Summ 41(6): 1–12.

Bachevalier J. 1996. Brief report: Medial temporal lobe and autism: A putative animal model in primates. J Autism Dev Disord 26(2): 217–220.

Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. 1995. Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol Med 25(1): 63–77.

Bauman M. 1999. Autism: Clinical features and neurobiological observations. Tager-Flusberg H. Neurodevelopmental Disorders. Cambridge, MA The MIT Press. Pp.383–399.

Bauman M, Kemper T. 1997. Neuroanatomic observations of the brain in autism. Bauman M , Kemper T , eds. The Neurobiology of Autism. Baltimore: The Johns Hopkins University Press. Pp. 119–145.

Berger R, Just M. 1988. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 16(4): 275–279.

Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C, Wang E, Ford-Jones EL, Cox P, Becker L, Fearon M, Petric M, Tellier R. 1999. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 29(4): 855–861.

Black S. 1994. Naltrexone in infantile autism. J Autism Dev Disord 24: 236–239.

Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR. 1985. Health impact of measles vaccination in the United States. Pediatrics 76(4): 524–532.

Bostrom A. 1997. Vaccine risk communication: Lessons from risk perception, decision making, and environmental risk communication research. Risk Health Safety Environ 8: 173–200.

Braun MM, Ellenberg SS. 1997. Descriptive epidemiology of adverse events after immunization: Reports to the Vaccine Adverse Event Reporting System (VAERS), 1991–1994. J Pediatr 131(4): 529–535.

Bristol MM, Cohen DJ, Costello EJ, Denckla M, Eckberg TJ, Kallen R, Kraemer HC, Lord C, Maurer R, McIlvane WJ, Minshew N, Sigman M, Spence MA. 1996. State of the science in autism: Report to the National Institutes of Health. J Autism Dev Disord 26(2): 121–154.

Bristol-Power M. 2001. Presentation to Immunization Safety Review Committee. Etiology of Autism: March 8, 2001; Washington, DC .

Burd L, Fisher W, Kerbeshian J. 1987. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatry 26(5): 700–703.

California Department of Developmental Services, Health and Human Services Agency. 1999. Changes in the Population of Persons With Autism and Pervasive Developmental Disorders in California's Developmental Services System: 1987 Through 1998. A Report to the Legislature. California Health and Human Services Agency. State of California.

Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. 1993. Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32: 1263–1271.

Carbone K, Park S, Rubin S, Waltrip R, Vogelsang G. 1991. Borna disease: Association with a maturation defect in the cellular immune response. J Virol 65(11): 6154–6164.